BioSpace News Archive

The Curiosity Cube, a 22x10-foot shipping container turned mobile science lab from MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, has been hard at work sparking kids’ interest in STEM careers on its fifth annual U.S tour.

Inventiva (Euronext Paris and Nasdaq: IVA), and Hepalys Pharma, Inc. have entered into an exclusive licensing agreement (the “Agreement”) to develop and commercialize Inventiva’s proprietary drug candidate lanifibranor for the treatment of non-alcoholic steatohepatitis (NASH) in Japan and South Korea.

Veru Inc. (NASDAQ: VERU) today announced that Mitchell Steiner, M.D., Chairman, President and Chief Executive Officer of Veru, will participate in a fireside chat at the 2023 Cantor Fitzgerald Global Healthcare Conference to be held at the InterContinental New York, Barclay Hotel in New York City on September 28th, 2023 at 10:55 a.m. ET.

Inozyme Pharma, Inc. today announced that it will host an Investor and Analyst Event on Tuesday, September 26, 2023 at 8:00 a.m. Eastern Time.

Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a company pioneering drug-eluting biomatrix products, today announced that Dr. Randy Mills, President and Chief Executive Officer, will participate on a panel at the Cantor Global Healthcare Conference.

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson’s disease (“PD”), Parkinson’s-related disorders and other diseases of the Abelson Tyrosine Kinases, today issued a Letter to Shareholders in response to recent price volatility.

Day Zero Diagnostics Inc. announced today the recent completion of a $16M round of financing.

Relmada Therapeutics, Inc. today announced efficacy results for the de novo (or new to treatment) patients (204 patients) and safety results for all subjects (627 patients) from the Phase 3, long-term, open-label, registrational trial (Study 310) of REL-1017 in patients with Major Depressive Disorder (MDD).

PhenomeX Inc. today announced it will showcase their latest optofluidic and proteomic technologies, along with customer partners, at two upcoming cell biology conferences.

Metadeq Diagnostics, Inc. announced the presentation of three posters at the EASL SLD Summit 2023 in Prague, Czech Republic.